Friday, July 10, 2026

pharma · Gram-negative Bacterial Infections · SARS-CoV-2 Infection

Shionogi Inc. (U.S.)

Shionogi Inc. (U.S.) clinical programs — 4 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Florham Park, USA HQ
2001 Founded
601 Employees
EMA registrant Type
Company details
Intelligence · Clinical Programs

Shionogi Inc. (U.S.) projects

4 ClinicalTrials.gov programs sponsored by Shionogi Inc. (U.S.).

Shionogi Inc. (U.S.) has 4 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

Clinical programs

  1. 2402T1432

    Shionogi B.V.

    Respiratory Syncytial Virus

    phase 2 other active

    1 trial
  2. Cefiderocol

    Shionogi B.V.

    Gram-negative Bacterial Infections

    phase 2 small molecule completed

    1 trial
  3. S-337395

    Shionogi B.V.

    Respiratory Syncytial Virus Infections

    phase 2 small molecule active

    1 trial
  4. S-606001 matching placebo, S-606001

    Shionogi B.V.

    Late-onset Pompe disease.

    phase 2 small molecule active

    1 trial

Frequently asked questions

How many clinical projects does Shionogi Inc. (U.S.) have?

4 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.